Global Cell Line Development Market Overview

The Global Cell Line Development Market size was valued at USD 6.74 billion in 2021 and is projected to reach USD 12.09 billion by 2028, growing at a CAGR of 8.7% from 2022 to 2028.

The process of co-opting the cellular machinery to create therapeutic biologics or other proteins of interest is known as cell line development. Cell line development can be done using a variety of expression systems, including bacterial, plant-based, yeast, and mammalian. Chinese hamster ovary (CHO) cells, grown in suspension cultures for ultimate use in bioreactors at the manufacturing stage, are the most widely utilized for the production of complex proteins. In recent years, molecular tools like zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs), and, most recently, the CRISPR/Cas9 system have enhanced gene editing. When it comes to designing cell lines for optimal biotherapeutic output, these strategies have resulted in significant increases in accuracy and ease of use.

Furthermore, the increased production of biosimilars as a result of the patent expiration of branded therapeutics and recombinant proteins is expected to stimulate demand. During the projection period, rising chronic disease prevalence demands better treatment solutions, and increasing demand for biosimilars, vaccines, therapeutic proteins, and new pharmaceuticals. Human cell lines used in vaccine manufacture include the WI-38 cell line created in the United States and the MRC-5 cell line developed in the United Kingdom. Polio, rotavirus, smallpox, and Japanese encephalitis are all treated with vaccines made utilizing animal cells. Hepatitis A, rubella, varicella, zoster, adenovirus type 4 and 7 oral, and rabies vaccinations are among the vaccines manufactured using cell lines. The growing prevalence of infectious diseases is anticipated to support the growth of the cell line development market over the forecasted period.

Market Dynamics and Factors for Cell Line Development

Drivers:

Growing applications in vaccine production and research

In research, immortal cell lines are frequently used in place of primary cells. They have several advantages, including being cost-effective, simple to use, providing an infinite supply of material, and avoiding ethical concerns associated with the usage of animal and human tissue. Cell lines also provide a pure population of cells, which is advantageous as it ensures a consistent sample and reproducible results. Cell lines have revolutionized scientific research and are now used in vaccine production, drug metabolism and cytotoxicity testing, antibody production, gene function studies, the generation of artificial tissues (e.g., artificial skin), and the synthesis of biological compounds such as therapeutic proteins. The numerous publications that use cell lines and the American Type Culture Collection (ATCC) Cell Biology Collection, which contains over 3,600 cell lines from over 150 different species, can be used to estimate cell line popularity.

The cell lines that are currently being utilized in the production of vaccines have been collected decades ago. Fetal cells are one of the most utilized cell lines for the production of vaccines. For instance, Leonard Hayflick has frozen ten million human fetal lung cells—derived from an aborted fetus in the early 1960s—in 700 glass vials after the original cell population had doubled seven times. Given their ability to double at least another 30 times, each vial can produce tens of thousands of kilos of WI-38 cells, enough to supply the world's vaccine manufacturers for several years. WI-38 is the name of the cell line and is the oldest fetal cell strain. These lung cells are predominantly utilized for the production of vaccines for varicella, rubella, hepatitis A, and rabies thus, supporting the development of the cell line development market during the analysis period.

The production of COVID-19 vaccines using fetal cell lines

The emergence of COVID-19 increased the usage of cell lines to develop effective vaccines in a short time. For instance, the PER.C6 cell line is derived from immortalized retinal cells from an 18-week-old fetus aborted in 1985. Johnson & Johnson used this cell line to create the COVID-19 vaccine. These cells were used to grow adenoviruses that had been modified so that they would not replicate or cause disease, which was then purified and used to deliver the genetic code for SARS-CoV-2's signature spike protein. The J&J vaccine does not contain any of the adenoviruses.

Pfizer and Moderna used HEK-293, an immortal cell line derived from the kidney of an aborted fetus in the 1970s for the production of its COVID-19 vaccine. During development, the cells were used to confirm that the genetic instructions for producing the SARS-CoV-2 spike protein worked in human cells. According to Alessondra Speidel, the cell lines were used as a proof-of-concept test, and neither of these mRNA vaccines was produced using fetal cells. Thus, the growing prevalence of viral outbreaks and the need to develop efficient vaccines to prevent viral outbreaks are the main factors supporting the growth of the cell line development market in the projected timeframe.

Restraints:

Cross Contamination and Continuous Passage Can Alter Genotype and Phenotype

Cell lines should have functional features that are as close to primary cells as possible. Since cell lines are genetically manipulated, their phenotype, native functions, and responsiveness to stimuli may change. Serial passage of cell lines can result in genotypic and phenotypic variation over time, and genetic drift can also result in heterogeneity in cultures at a single point in time. As a result, cell lines may not accurately represent primary cells and may produce inconsistent results. Furthermore, contamination with other cell lines and mycoplasma are major issues associated with the usage of cell lines. Cross Contamination was reported for the first time in the early 1970s by Walter Nelson-Rees. When a rapidly proliferating cell line is introduced into a cell line, it only takes a few passages for the culture to be completely taken over by the contaminating cell line. Such issues are well known to be caused by HeLa cell contamination. Furthermore, mycoplasma contamination can persist undetected in cell cultures for long periods, causing significant changes in gene expression and cell behavior thus, hampering the growth of the cell line development market over the forecasted period.

Opportunities:

Technological Advancements to Enhance the Manufacturing Process of Cell Lines

Cell Line Engineering (CLE) methods and 3D cell culture are novel approaches based on obtaining human primary cells and/or animal cells from root tissues, growing them in all three dimensions with selective media, and allowing cells to form sphere-shaped aggregates known as spheroids. Growth conditions for 3D cell cultures include several raw materials, altogether known as scaffolds.  CLE is an advanced technology that allows businesses to design cell lines using CRISPR products. According to the research project requirements requested by their collaborating clients, Thermo Fisher Scientific is engineering new cell lines using a wide variety of already available cell lines. This makes cancer cell research, artificial organ growth, and new treatments more relevant to live human tissues, while also eliminating contamination and uncontrolled mutations.

Investment by prominent companies is further stimulating the expansion of the market over the analysis period. For instance, in June 2022, FUJIFILM Corporation announced a USD 1.6 billion investment to improve and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a FUJIFILM Corporation subsidiary and world-leading contract development and manufacturing organization (CDMO). This investment will help FUJIFILM Diosynth Biotechnologies' facilities in Hillerød, Denmark, and Texas, USA. Thus, investment in R&D, manufacturing facilities, and the development of innovative technologies for the production of a cell line are anticipated to create lucrative opportunities for the market players.

Segmentation Analysis of the Cell Line Development Market

By Product, the reagents & media segment is anticipated to have the highest share of the market over the analysis period. Reagents for cell culture are crucial to the success of physiologically relevant cell models in biomedical research and bioproduction. Media, sera, and supplements are essential to culture reagents that promote cell survival, proliferation, and biological function. Antibiotics and amino acid supplements are common cell culture reagents. Furthermore, the quality of these reagents has a direct impact on experimental results and biological production. Media utilized for the production of stable cell lines is of two types: natural and synthetic. Synthetic media is the most widely utilized culture medium as it contains all the essential supplements for the growth of cell lines. The concentration of the supplement can be altered to match the development of the specific cell line. The growing demand for biologic therapeutics necessitates an appropriate growth environment to increase production thus, increasing the demand for reagents & media.  

By Source, the mammalian segment is expected to lead the growth of the cell line development market over the analysis period. Protein production in sufficient quantity and quality is a critical requirement. There has been a gradual increase in the use of mammalian cells for protein production. Mammalian cell-based expression systems for recombinant proteins can introduce proper protein folding, post-translational modifications, and product assembly, all of which are required for complete biological activity. Mammalian cell lines are used to create biological products like antibodies, synthetic hormones, and enzymes. For instance, Cerezyme, a recombinant enzyme produced in mammalian cells, can be used to treat patients with Gaucher's disease, a congenital disorder characterized by a lack of the functional enzyme β-glucocerebrosidase. thereby, supporting the growth of the segment.

By Type Of Cell Line, the recombinant cell line segment is anticipated to dominate the market in the projected period. One of humanity's most pressing needs is the mass production of therapeutic proteins for the treatment of diseases that affect millions of people. Recent advancements in recombinant DNA technologies have paved the way for the development of recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents. Recombinant proteins for these applications are primarily produced in the laboratory and large-scale settings using prokaryotic and eukaryotic expression host systems such as mammalian cells, bacteria, yeast, insect cells, and transgenic plants. These expression cell lines have fewer side effects and perform better during biological processes thus, strengthening the development of the segment in the forecasted period.

By Application, the bioproduction segment is forecasted to have the highest share of the market. Protein therapeutics, which include monoclonal antibodies [mAbs], peptides, and recombinant proteins, is the biopharmaceutical industry's largest group of new products in development. The most commonly used expression system for mAb production in mammalian cells. The primary advantage of a mammalian expression system is that the cellular machinery is designed to produce, process, and secrete highly complex molecules. The vast majority of commercial mAbs are produced in Chinese hamster ovary (CHO) and NS0 cells, which are derived from plasmacytoma cells that have been modified to produce IgG in nonsecreting B cells. Genetic changes in CHO cells have resulted in cell lines capable of producing a large number of humanized mAbs. With the growing demand for personalized medications coupled with the continuous rising need for other biotherapeutics products, the future of the bioproduct segment is bright.

Regional Analysis Of the Cell Line Development Market

The North American region is anticipated to have the highest share of the cell line development market in the forecasted period. The growing prevalence of cancer and seasonal flu has promoted the usage of cell lines for developing innovative treatment methods. According to the American Cancer Society, 1.9 million new cancer cases are expected to be diagnosed in 2021. In 2021, an estimated 608,570 Americans will succumb to cancer, equating to approximately 1,670 deaths per day. Cancer is the second leading cause of death in the United States, trailing only heart disease. Human cancer-derived cell lines are basic models used in laboratories to study cancer biology and the therapeutic efficacy of anticancer agents. The first cultured cancer line was HeLa. It was created from Henrietta Lacks' cervical cancer cells in 1951. Since then several cancer cell lines have been developed by institutes in the USA, and Canada. Thus, the growing prevalence of cancer cases is anticipated to drive the growth of the cell line development market in this region.

The European region is expected to have the second-highest share of the cell line development market owing to the presence of prominent key players and research institutes. Cell lines are utilized to study a wide array of characteristics from protein production to virus propagation. Applied Biological Materials in Richmond, British Columbia, for instance, sells complete kits for immortalizing cells with hTERT, with or without additional oncogenes. BioCat GmbH in Heidelberg, Germany, also sells established cell lines and cell immortalization reagents. Researchers can also send their primary cells directly to BioCat and allow the company to develop the cell lines. Furthermore, in October 2021, UGA Biopharma showcased its fast-track cell line development platforms, ready-to-use biosimilar cell lines, and First CHOice® Media and Feeds at the BIO-Europe® Digital Edition conference. First CHOice® Medium has several advantages for high-performance cell culture optimized for mammalian cell lines. It has been optimized for cell growth and productivity in batch, fed-batch, and perfusion processes when combined with CHOice® Feeds. The growing competition in the European market represents a healthy environment for the development of the cell line development market in this region.

The cell line development market in the Asia-Pacific region is anticipated to develop at a significant growth rate over the analysis period. India, China, South Korea, Japan, Australia, and Singapore are some of the prominent countries in this region supporting the development of the market. For instance, in July 2022, Researchers from the Mumbai unit of the National Institute of Virology (NIV) used the cutting-edge gene-editing tool, CRISPR/Cas9, to develop a poliovirus-free cell line for use in research work in laboratories. The NIV Mumbai's polio-free cell line is important in the backdrop of the global polio eradication program. In addition, in March 2022, the Japanese Ministry of Health, Labor, and Welfare (MHLW) approved Xenpozyme® (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially fatal genetic disease. Xenpozyme is currently the only approved treatment for ASMD, and it is Sanofi's first therapy to be approved under the SAKIGAKE (or "pioneer") designation. From discovery, and trials, to the production of these biological therapeutics, cell lines played an important role thus, similar initiatives in other countries will further strengthen the growth of the cell line development market in this region.

COVID-19 Impact on Cell Line Development Market

The COVID-19 pandemic has significantly disrupted scientific activities. Labs were forced to shut down. Researchers were placed on leave and advised to work from home. Animal facilities were also reduced, and research supplies were delayed in shipping. Despite these obstacles, many researchers remained undeterred and applied their scientific knowledge to combat SARS-CoV-2, the coronavirus responsible for COVID-19. Furthermore, the pandemic accelerated vaccine development and, in an unprecedented case, inspired companies with competing interests to collaborate in efforts to address this global health crisis. Cell cultures, including immortalized cell lines, stem cell lines, and patient-derived primary cells, were used as in vitro models to study viral entry into human cells. They were used for drug screening and as cellular factories to produce viral particles for testing. This aided in the development of appropriate cell lines for high-throughput testing of antiviral medications. Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), two essential host proteins required for viral entry, were engineered to express at high levels in the human lung carcinoma cell line A549, according to a study published in the Journal of Virus in March 2022. As a result, more cell lines for COVID-19 management are being developed thus, supporting the development of the cell line development market.

Top Key Players Covered in Cell Line Development Market

• GE Healthcare
• Sartorious AG
• Corning Inc.
• WuXi AppTec Inc.
• Selexis SA
• Sigma-Aldrich Corporation
• Lonza Group AG
• Sartorius
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• Promega Corporation
• Beckman Coulter Inc.
• European Collection of Cell Cultures, and Other Major Players.

Key Industry Developments in Cell Line Development Market

In September 2022, Sartorius, a life science company, completed the acquisition of Albumedix Ltd. through its French-listed subsidiary Sartorius Stedim Biotech. Albumedix, based in Nottingham, UK, is a market leader in recombinant albumin-based solutions.

In July 2022, Granite Bio and ProBioGen joined forces to provide GMP manufacturing and cell line development services. Granite Bio's lead candidate for the treatment of autoimmune and specific cancer indications is a novel monoclonal antibody.

In January 2021, Thermo Fisher Scientific created a novel medium for the development and expansion of human T lymphocytes (T-cells) for cell therapy developers employing allogeneic workflows. The Gibco CTS OpTmizer Pro Serum-Free Media (SFM) is a first-of-its-kind media solution that addresses the metabolism of healthy donor cells, making it ideal for use in the creation of allogeneic, off-the-shelf cell treatments.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Product
 3.2 By Source
 3.3 By Cell Line Type
 3.4 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Cell Line Development Market by Product
 5.1 Cell Line Development Market Overview Snapshot and Growth Engine
 5.2 Cell Line Development Market Overview
 5.3 Equipment
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Equipment: Geographic Segmentation
 5.4 Reagents & Media
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Reagents & Media: Geographic Segmentation
 5.5 Accessories & Consumables
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Accessories & Consumables: Geographic Segmentation

Chapter 6: Cell Line Development Market by Source
 6.1 Cell Line Development Market Overview Snapshot and Growth Engine
 6.2 Cell Line Development Market Overview
 6.3 Mammalian
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Mammalian: Geographic Segmentation
 6.4 Non-Mammalian
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Non-Mammalian: Geographic Segmentation

Chapter 7: Cell Line Development Market by Cell Line Type
 7.1 Cell Line Development Market Overview Snapshot and Growth Engine
 7.2 Cell Line Development Market Overview
 7.3 Recombinant Cell Lines
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Recombinant Cell Lines: Geographic Segmentation
 7.4 Hybridomas
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Hybridomas: Geographic Segmentation
 7.5 Continuous Cell Lines
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Continuous Cell Lines: Geographic Segmentation
 7.6 Primary Cell Lines
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size (2016-2028F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Primary Cell Lines: Geographic Segmentation

Chapter 8: Cell Line Development Market by Application
 8.1 Cell Line Development Market Overview Snapshot and Growth Engine
 8.2 Cell Line Development Market Overview
 8.3 Bioproduction
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size (2016-2028F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Bioproduction: Geographic Segmentation
 8.4 Drug Discovery
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size (2016-2028F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Drug Discovery: Geographic Segmentation
 8.5 Toxicity Testing
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size (2016-2028F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Toxicity Testing: Geographic Segmentation
 8.6 Tissue Engineering
  8.6.1 Introduction and Market Overview
  8.6.2 Historic and Forecasted Market Size (2016-2028F)
  8.6.3 Key Market Trends, Growth Factors and Opportunities
  8.6.4 Tissue Engineering: Geographic Segmentation
 8.7 Research
  8.7.1 Introduction and Market Overview
  8.7.2 Historic and Forecasted Market Size (2016-2028F)
  8.7.3 Key Market Trends, Growth Factors and Opportunities
  8.7.4 Research: Geographic Segmentation

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Positioning
  9.1.2 Cell Line Development Sales and Market Share By Players
  9.1.3 Industry BCG Matrix
  9.1.4 Ansoff Matrix
  9.1.5 Cell Line Development Industry Concentration Ratio (CR5 and HHI)
  9.1.6 Top 5 Cell Line Development Players Market Share
  9.1.7 Mergers and Acquisitions
  9.1.8 Business Strategies By Top Players
 9.2 GE HEALTHCARE
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Operating Business Segments
  9.2.5 Product Portfolio
  9.2.6 Business Performance
  9.2.7 Key Strategic Moves and Recent Developments
  9.2.8 SWOT Analysis
 9.3 SARTORIOUS AG
 9.4 CORNING INC.
 9.5 WUXI APPTEC INC.
 9.6 SELEXIS SA
 9.7 SIGMA-ALDRICH CORPORATION
 9.8 LONZA GROUP AG
 9.9 SARTORIUS
 9.10 THERMO FISHER SCIENTIFIC INC.
 9.11 DANAHER CORPORATION
 9.12 MERCK KGAA
 9.13 PROMEGA CORPORATION
 9.14 BECKMAN COULTER INC.
 9.15 EUROPEAN COLLECTION OF CELL CULTURES
 9.16 OTHER MAJOR PLAYERS

Chapter 10: Global Cell Line Development Market Analysis, Insights and Forecast, 2016-2028
 10.1 Market Overview
 10.2 Historic and Forecasted Market Size By Product
  10.2.1 Equipment
  10.2.2 Reagents & Media
  10.2.3 Accessories & Consumables
 10.3 Historic and Forecasted Market Size By Source
  10.3.1 Mammalian
  10.3.2 Non-Mammalian
 10.4 Historic and Forecasted Market Size By Cell Line Type
  10.4.1 Recombinant Cell Lines
  10.4.2 Hybridomas
  10.4.3 Continuous Cell Lines
  10.4.4 Primary Cell Lines
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Bioproduction
  10.5.2 Drug Discovery
  10.5.3 Toxicity Testing
  10.5.4 Tissue Engineering
  10.5.5 Research

Chapter 11: North America Cell Line Development Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Product
  11.4.1 Equipment
  11.4.2 Reagents & Media
  11.4.3 Accessories & Consumables
 11.5 Historic and Forecasted Market Size By Source
  11.5.1 Mammalian
  11.5.2 Non-Mammalian
 11.6 Historic and Forecasted Market Size By Cell Line Type
  11.6.1 Recombinant Cell Lines
  11.6.2 Hybridomas
  11.6.3 Continuous Cell Lines
  11.6.4 Primary Cell Lines
 11.7 Historic and Forecasted Market Size By Application
  11.7.1 Bioproduction
  11.7.2 Drug Discovery
  11.7.3 Toxicity Testing
  11.7.4 Tissue Engineering
  11.7.5 Research
 11.8 Historic and Forecast Market Size by Country
  11.8.1 U.S.
  11.8.2 Canada
  11.8.3 Mexico

Chapter 12: Europe Cell Line Development Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Product
  12.4.1 Equipment
  12.4.2 Reagents & Media
  12.4.3 Accessories & Consumables
 12.5 Historic and Forecasted Market Size By Source
  12.5.1 Mammalian
  12.5.2 Non-Mammalian
 12.6 Historic and Forecasted Market Size By Cell Line Type
  12.6.1 Recombinant Cell Lines
  12.6.2 Hybridomas
  12.6.3 Continuous Cell Lines
  12.6.4 Primary Cell Lines
 12.7 Historic and Forecasted Market Size By Application
  12.7.1 Bioproduction
  12.7.2 Drug Discovery
  12.7.3 Toxicity Testing
  12.7.4 Tissue Engineering
  12.7.5 Research
 12.8 Historic and Forecast Market Size by Country
  12.8.1 Germany
  12.8.2 U.K.
  12.8.3 France
  12.8.4 Italy
  12.8.5 Russia
  12.8.6 Spain
  12.8.7 Rest of Europe

Chapter 13: Asia-Pacific Cell Line Development Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Product
  13.4.1 Equipment
  13.4.2 Reagents & Media
  13.4.3 Accessories & Consumables
 13.5 Historic and Forecasted Market Size By Source
  13.5.1 Mammalian
  13.5.2 Non-Mammalian
 13.6 Historic and Forecasted Market Size By Cell Line Type
  13.6.1 Recombinant Cell Lines
  13.6.2 Hybridomas
  13.6.3 Continuous Cell Lines
  13.6.4 Primary Cell Lines
 13.7 Historic and Forecasted Market Size By Application
  13.7.1 Bioproduction
  13.7.2 Drug Discovery
  13.7.3 Toxicity Testing
  13.7.4 Tissue Engineering
  13.7.5 Research
 13.8 Historic and Forecast Market Size by Country
  13.8.1 China
  13.8.2 India
  13.8.3 Japan
  13.8.4 Singapore
  13.8.5 Australia
  13.8.6 New Zealand
  13.8.7 Rest of APAC

Chapter 14: Middle East & Africa Cell Line Development Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Product
  14.4.1 Equipment
  14.4.2 Reagents & Media
  14.4.3 Accessories & Consumables
 14.5 Historic and Forecasted Market Size By Source
  14.5.1 Mammalian
  14.5.2 Non-Mammalian
 14.6 Historic and Forecasted Market Size By Cell Line Type
  14.6.1 Recombinant Cell Lines
  14.6.2 Hybridomas
  14.6.3 Continuous Cell Lines
  14.6.4 Primary Cell Lines
 14.7 Historic and Forecasted Market Size By Application
  14.7.1 Bioproduction
  14.7.2 Drug Discovery
  14.7.3 Toxicity Testing
  14.7.4 Tissue Engineering
  14.7.5 Research
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Turkey
  14.8.2 Saudi Arabia
  14.8.3 Iran
  14.8.4 UAE
  14.8.5 Africa
  14.8.6 Rest of MEA

Chapter 15: South America Cell Line Development Market Analysis, Insights and Forecast, 2016-2028
 15.1 Key Market Trends, Growth Factors and Opportunities
 15.2 Impact of Covid-19
 15.3 Key Players
 15.4 Key Market Trends, Growth Factors and Opportunities
 15.4 Historic and Forecasted Market Size By Product
  15.4.1 Equipment
  15.4.2 Reagents & Media
  15.4.3 Accessories & Consumables
 15.5 Historic and Forecasted Market Size By Source
  15.5.1 Mammalian
  15.5.2 Non-Mammalian
 15.6 Historic and Forecasted Market Size By Cell Line Type
  15.6.1 Recombinant Cell Lines
  15.6.2 Hybridomas
  15.6.3 Continuous Cell Lines
  15.6.4 Primary Cell Lines
 15.7 Historic and Forecasted Market Size By Application
  15.7.1 Bioproduction
  15.7.2 Drug Discovery
  15.7.3 Toxicity Testing
  15.7.4 Tissue Engineering
  15.7.5 Research
 15.8 Historic and Forecast Market Size by Country
  15.8.1 Brazil
  15.8.2 Argentina
  15.8.3 Rest of SA

Chapter 16 Investment Analysis

Chapter 17 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. CELL LINE DEVELOPMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. CELL LINE DEVELOPMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. CELL LINE DEVELOPMENT MARKET COMPETITIVE RIVALRY
TABLE 005. CELL LINE DEVELOPMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. CELL LINE DEVELOPMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. CELL LINE DEVELOPMENT MARKET BY PRODUCT
TABLE 008. EQUIPMENT MARKET OVERVIEW (2016-2028)
TABLE 009. REAGENTS & MEDIA MARKET OVERVIEW (2016-2028)
TABLE 010. ACCESSORIES & CONSUMABLES MARKET OVERVIEW (2016-2028)
TABLE 011. CELL LINE DEVELOPMENT MARKET BY SOURCE
TABLE 012. MAMMALIAN MARKET OVERVIEW (2016-2028)
TABLE 013. NON-MAMMALIAN MARKET OVERVIEW (2016-2028)
TABLE 014. CELL LINE DEVELOPMENT MARKET BY CELL LINE TYPE
TABLE 015. RECOMBINANT CELL LINES MARKET OVERVIEW (2016-2028)
TABLE 016. HYBRIDOMAS MARKET OVERVIEW (2016-2028)
TABLE 017. CONTINUOUS CELL LINES MARKET OVERVIEW (2016-2028)
TABLE 018. PRIMARY CELL LINES MARKET OVERVIEW (2016-2028)
TABLE 019. CELL LINE DEVELOPMENT MARKET BY APPLICATION
TABLE 020. BIOPRODUCTION MARKET OVERVIEW (2016-2028)
TABLE 021. DRUG DISCOVERY MARKET OVERVIEW (2016-2028)
TABLE 022. TOXICITY TESTING MARKET OVERVIEW (2016-2028)
TABLE 023. TISSUE ENGINEERING MARKET OVERVIEW (2016-2028)
TABLE 024. RESEARCH MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA CELL LINE DEVELOPMENT MARKET, BY PRODUCT (2016-2028)
TABLE 026. NORTH AMERICA CELL LINE DEVELOPMENT MARKET, BY SOURCE (2016-2028)
TABLE 027. NORTH AMERICA CELL LINE DEVELOPMENT MARKET, BY CELL LINE TYPE (2016-2028)
TABLE 028. NORTH AMERICA CELL LINE DEVELOPMENT MARKET, BY APPLICATION (2016-2028)
TABLE 029. N CELL LINE DEVELOPMENT MARKET, BY COUNTRY (2016-2028)
TABLE 030. EUROPE CELL LINE DEVELOPMENT MARKET, BY PRODUCT (2016-2028)
TABLE 031. EUROPE CELL LINE DEVELOPMENT MARKET, BY SOURCE (2016-2028)
TABLE 032. EUROPE CELL LINE DEVELOPMENT MARKET, BY CELL LINE TYPE (2016-2028)
TABLE 033. EUROPE CELL LINE DEVELOPMENT MARKET, BY APPLICATION (2016-2028)
TABLE 034. CELL LINE DEVELOPMENT MARKET, BY COUNTRY (2016-2028)
TABLE 035. ASIA PACIFIC CELL LINE DEVELOPMENT MARKET, BY PRODUCT (2016-2028)
TABLE 036. ASIA PACIFIC CELL LINE DEVELOPMENT MARKET, BY SOURCE (2016-2028)
TABLE 037. ASIA PACIFIC CELL LINE DEVELOPMENT MARKET, BY CELL LINE TYPE (2016-2028)
TABLE 038. ASIA PACIFIC CELL LINE DEVELOPMENT MARKET, BY APPLICATION (2016-2028)
TABLE 039. CELL LINE DEVELOPMENT MARKET, BY COUNTRY (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET, BY PRODUCT (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET, BY SOURCE (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET, BY CELL LINE TYPE (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET, BY APPLICATION (2016-2028)
TABLE 044. CELL LINE DEVELOPMENT MARKET, BY COUNTRY (2016-2028)
TABLE 045. SOUTH AMERICA CELL LINE DEVELOPMENT MARKET, BY PRODUCT (2016-2028)
TABLE 046. SOUTH AMERICA CELL LINE DEVELOPMENT MARKET, BY SOURCE (2016-2028)
TABLE 047. SOUTH AMERICA CELL LINE DEVELOPMENT MARKET, BY CELL LINE TYPE (2016-2028)
TABLE 048. SOUTH AMERICA CELL LINE DEVELOPMENT MARKET, BY APPLICATION (2016-2028)
TABLE 049. CELL LINE DEVELOPMENT MARKET, BY COUNTRY (2016-2028)
TABLE 050. GE HEALTHCARE: SNAPSHOT
TABLE 051. GE HEALTHCARE: BUSINESS PERFORMANCE
TABLE 052. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 053. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. SARTORIOUS AG: SNAPSHOT
TABLE 054. SARTORIOUS AG: BUSINESS PERFORMANCE
TABLE 055. SARTORIOUS AG: PRODUCT PORTFOLIO
TABLE 056. SARTORIOUS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. CORNING INC.: SNAPSHOT
TABLE 057. CORNING INC.: BUSINESS PERFORMANCE
TABLE 058. CORNING INC.: PRODUCT PORTFOLIO
TABLE 059. CORNING INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. WUXI APPTEC INC.: SNAPSHOT
TABLE 060. WUXI APPTEC INC.: BUSINESS PERFORMANCE
TABLE 061. WUXI APPTEC INC.: PRODUCT PORTFOLIO
TABLE 062. WUXI APPTEC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. SELEXIS SA: SNAPSHOT
TABLE 063. SELEXIS SA: BUSINESS PERFORMANCE
TABLE 064. SELEXIS SA: PRODUCT PORTFOLIO
TABLE 065. SELEXIS SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. SIGMA-ALDRICH CORPORATION: SNAPSHOT
TABLE 066. SIGMA-ALDRICH CORPORATION: BUSINESS PERFORMANCE
TABLE 067. SIGMA-ALDRICH CORPORATION: PRODUCT PORTFOLIO
TABLE 068. SIGMA-ALDRICH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. LONZA GROUP AG: SNAPSHOT
TABLE 069. LONZA GROUP AG: BUSINESS PERFORMANCE
TABLE 070. LONZA GROUP AG: PRODUCT PORTFOLIO
TABLE 071. LONZA GROUP AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. SARTORIUS: SNAPSHOT
TABLE 072. SARTORIUS: BUSINESS PERFORMANCE
TABLE 073. SARTORIUS: PRODUCT PORTFOLIO
TABLE 074. SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 075. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 076. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 077. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. DANAHER CORPORATION: SNAPSHOT
TABLE 078. DANAHER CORPORATION: BUSINESS PERFORMANCE
TABLE 079. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 080. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. MERCK KGAA: SNAPSHOT
TABLE 081. MERCK KGAA: BUSINESS PERFORMANCE
TABLE 082. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 083. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. PROMEGA CORPORATION: SNAPSHOT
TABLE 084. PROMEGA CORPORATION: BUSINESS PERFORMANCE
TABLE 085. PROMEGA CORPORATION: PRODUCT PORTFOLIO
TABLE 086. PROMEGA CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. BECKMAN COULTER INC.: SNAPSHOT
TABLE 087. BECKMAN COULTER INC.: BUSINESS PERFORMANCE
TABLE 088. BECKMAN COULTER INC.: PRODUCT PORTFOLIO
TABLE 089. BECKMAN COULTER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 089. EUROPEAN COLLECTION OF CELL CULTURES: SNAPSHOT
TABLE 090. EUROPEAN COLLECTION OF CELL CULTURES: BUSINESS PERFORMANCE
TABLE 091. EUROPEAN COLLECTION OF CELL CULTURES: PRODUCT PORTFOLIO
TABLE 092. EUROPEAN COLLECTION OF CELL CULTURES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 092. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 093. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 094. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 095. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. CELL LINE DEVELOPMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. CELL LINE DEVELOPMENT MARKET OVERVIEW BY PRODUCT
FIGURE 012. EQUIPMENT MARKET OVERVIEW (2016-2028)
FIGURE 013. REAGENTS & MEDIA MARKET OVERVIEW (2016-2028)
FIGURE 014. ACCESSORIES & CONSUMABLES MARKET OVERVIEW (2016-2028)
FIGURE 015. CELL LINE DEVELOPMENT MARKET OVERVIEW BY SOURCE
FIGURE 016. MAMMALIAN MARKET OVERVIEW (2016-2028)
FIGURE 017. NON-MAMMALIAN MARKET OVERVIEW (2016-2028)
FIGURE 018. CELL LINE DEVELOPMENT MARKET OVERVIEW BY CELL LINE TYPE
FIGURE 019. RECOMBINANT CELL LINES MARKET OVERVIEW (2016-2028)
FIGURE 020. HYBRIDOMAS MARKET OVERVIEW (2016-2028)
FIGURE 021. CONTINUOUS CELL LINES MARKET OVERVIEW (2016-2028)
FIGURE 022. PRIMARY CELL LINES MARKET OVERVIEW (2016-2028)
FIGURE 023. CELL LINE DEVELOPMENT MARKET OVERVIEW BY APPLICATION
FIGURE 024. BIOPRODUCTION MARKET OVERVIEW (2016-2028)
FIGURE 025. DRUG DISCOVERY MARKET OVERVIEW (2016-2028)
FIGURE 026. TOXICITY TESTING MARKET OVERVIEW (2016-2028)
FIGURE 027. TISSUE ENGINEERING MARKET OVERVIEW (2016-2028)
FIGURE 028. RESEARCH MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA CELL LINE DEVELOPMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE CELL LINE DEVELOPMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC CELL LINE DEVELOPMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA CELL LINE DEVELOPMENT MARKET OVERVIEW BY COUNTRY (2016-2028)